Investor Relations

AMS at a Glance

Advanced Medical Solutions Group plc is a leading developer and manufacturer of innovative and technologically advanced products for the global surgical and advanced woundcare markets.

Our primary focus is to create quality outcomes for our:

  • Customers
  • Patients
  • Shareholders

Financial Calendar

Full Year Period End

31 December 2020

Interim Results Announcement

September 2020 (TBC)

Half Year Period End

30 June 2020

Final Dividend Payment

19 June 2020

Annual General Meeting

10 June 2020 (Closed Meeting)

Preliminary Results Announcement

11 March 2020
View Full Calendar

Financial Reports

Notice of AGM

May 2020

2019 Interim Report

September 2019

2018 Interim Report

September 2018

2017 Interim Report

September 2017

2016 Interim Report

September 2016

2015 Interim Report

October 2015

2014 Interim Report

September 2014
View All Reports

News

Acquisition of Biomatlante

Advanced Medical Solutions Group plc today announces it has acquired French company Biomatlante SA (“Biomatlante”), a well-established international developer and manufacturer... Read More

Stifel UK Healthcare Seminar

AMS attended the Stifel UK Healthcare Seminar on 5 December 2019. Read More

View More News

Latest Financial Highlights

Summary

Whilst 2019 proved a challenging year for the Group, with the downturn of US LiquiBand® and the third-party sterilisation failure at the end of 2019 which was resolved in early 2020, we are pleased to report good growth in other areas of the business enabled the Group to deliver revenues of £102.4 million, broadly in line with 2018.

Adjusted profit before tax decreased by 7% to £26.6 million due to our operational investment in Sealantis, adverse sales mix and currency contracts. This contributed to a decrease of 8% in adjusted diluted earnings per share.

The Surgical Business Unit sales were restricted by US LiquiBand® performance, resulting in a 1% decrease in revenue to £56.5 million and by 2% at constant currency. We have made progress on the two key product approvals needed to support the recovery of LiquiBand® in the US. LiquiBand® Rapid™ was recently approved by the FDA and the LiquiBand® XL pilot clinical study is in progress and will be concluded by the end of Q1 2020.

Our Woundcare business grew 1% to £45.8 million but was flat at constant currency. We strengthened our woundcare portfolio in the year with US approvals for our antimicrobial PHMB foam and silver high-performance dressings, both of which were signed to partners and launched to the market in Q4 2019.

The acquisition of Biomatlante demonstrates our strategy of utilising our strong cash position to acquire businesses with complementary products, exciting technologies and new routes to market and the acquisition of Sealantis demonstrates our willingness to invest in longer term growth opportunities.